 Janine Oliver
Concepts (117)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pelvic Organ Prolapse | 2 | 2017 | 51 | 1.030 |
Why?
| | Urinary Incontinence, Stress | 3 | 2022 | 14 | 0.930 |
Why?
| | Robotic Surgical Procedures | 2 | 2019 | 138 | 0.600 |
Why?
| | Urethra | 2 | 2023 | 53 | 0.570 |
Why?
| | Surgical Mesh | 2 | 2022 | 52 | 0.560 |
Why?
| | Nitric Oxide Synthase Type III | 2 | 2018 | 205 | 0.540 |
Why?
| | Fascia | 1 | 2017 | 17 | 0.530 |
Why?
| | Urinary Bladder Neck Obstruction | 1 | 2017 | 20 | 0.530 |
Why?
| | Device Removal | 1 | 2017 | 135 | 0.490 |
Why?
| | Urologic Surgical Procedures | 1 | 2017 | 112 | 0.490 |
Why?
| | Postoperative Complications | 2 | 2017 | 2671 | 0.460 |
Why?
| | Clitoris | 1 | 2014 | 9 | 0.440 |
Why?
| | Osteoprotegerin | 1 | 2013 | 24 | 0.410 |
Why?
| | Suburethral Slings | 2 | 2022 | 7 | 0.390 |
Why?
| | Lower Urinary Tract Symptoms | 1 | 2013 | 60 | 0.370 |
Why?
| | Nitric Oxide | 1 | 2014 | 895 | 0.300 |
Why?
| | Melanoma | 2 | 2013 | 763 | 0.280 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1239 | 0.280 |
Why?
| | Laparoscopy | 3 | 2019 | 445 | 0.270 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2013 | 1388 | 0.270 |
Why?
| | Operative Time | 2 | 2017 | 146 | 0.260 |
Why?
| | Aldehyde Oxidoreductases | 2 | 2018 | 27 | 0.260 |
Why?
| | Stress, Psychological | 1 | 2013 | 1122 | 0.220 |
Why?
| | Mental Disorders | 1 | 2013 | 1093 | 0.210 |
Why?
| | Ureter | 2 | 2016 | 34 | 0.210 |
Why?
| | Urethral Stricture | 1 | 2023 | 14 | 0.200 |
Why?
| | Abdominal Injuries | 1 | 2022 | 120 | 0.170 |
Why?
| | Gynecologic Surgical Procedures | 2 | 2019 | 64 | 0.170 |
Why?
| | Obesity | 1 | 2013 | 3037 | 0.160 |
Why?
| | Fascia Lata | 1 | 2019 | 4 | 0.150 |
Why?
| | Uterine Prolapse | 1 | 2019 | 14 | 0.150 |
Why?
| | Penile Erection | 1 | 2018 | 8 | 0.150 |
Why?
| | Erectile Dysfunction | 1 | 2018 | 40 | 0.140 |
Why?
| | Retrospective Studies | 7 | 2023 | 15750 | 0.130 |
Why?
| | Treatment Outcome | 5 | 2023 | 10832 | 0.130 |
Why?
| | Urinary Catheterization | 1 | 2017 | 31 | 0.130 |
Why?
| | Phenazopyridine | 1 | 2016 | 1 | 0.130 |
Why?
| | Vagina | 1 | 2019 | 188 | 0.130 |
Why?
| | Fluorescein | 1 | 2016 | 24 | 0.130 |
Why?
| | Surgical Flaps | 1 | 2017 | 141 | 0.120 |
Why?
| | Intraoperative Complications | 1 | 2016 | 138 | 0.120 |
Why?
| | Female | 10 | 2023 | 73648 | 0.110 |
Why?
| | Fluorescent Dyes | 1 | 2016 | 318 | 0.110 |
Why?
| | Soluble Guanylyl Cyclase | 1 | 2014 | 15 | 0.110 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2014 | 22 | 0.110 |
Why?
| | Caveolin 1 | 1 | 2014 | 22 | 0.110 |
Why?
| | Guanylate Cyclase | 1 | 2014 | 37 | 0.110 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 2014 | 46 | 0.110 |
Why?
| | Endothelium | 1 | 2014 | 125 | 0.100 |
Why?
| | Muscle, Smooth | 1 | 2014 | 151 | 0.100 |
Why?
| | Osteoclasts | 1 | 2013 | 51 | 0.100 |
Why?
| | Missouri | 1 | 2013 | 60 | 0.100 |
Why?
| | Humans | 13 | 2023 | 138102 | 0.100 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2014 | 206 | 0.100 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2014 | 369 | 0.090 |
Why?
| | Endothelium, Vascular | 2 | 2018 | 934 | 0.090 |
Why?
| | Replantation | 1 | 2011 | 31 | 0.090 |
Why?
| | Vesico-Ureteral Reflux | 1 | 2011 | 33 | 0.090 |
Why?
| | Middle Aged | 5 | 2022 | 33509 | 0.080 |
Why?
| | Neoplasm Metastasis | 1 | 2013 | 664 | 0.080 |
Why?
| | Robotics | 1 | 2011 | 85 | 0.080 |
Why?
| | Phosphorylation | 1 | 2014 | 1760 | 0.080 |
Why?
| | Cell Membrane | 1 | 2013 | 713 | 0.080 |
Why?
| | Immunotherapy | 1 | 2013 | 631 | 0.070 |
Why?
| | Comorbidity | 1 | 2013 | 1638 | 0.070 |
Why?
| | Cell Line, Tumor | 2 | 2013 | 3404 | 0.070 |
Why?
| | beta 2-Microglobulin | 1 | 2006 | 50 | 0.060 |
Why?
| | HLA-A Antigens | 1 | 2006 | 57 | 0.060 |
Why?
| | Genes, MHC Class I | 1 | 2006 | 36 | 0.060 |
Why?
| | Incidence | 1 | 2013 | 2827 | 0.060 |
Why?
| | Adult | 3 | 2017 | 38063 | 0.060 |
Why?
| | Quality of Life | 1 | 2017 | 2936 | 0.060 |
Why?
| | Cytokines | 1 | 2013 | 2079 | 0.060 |
Why?
| | Antigen Presentation | 1 | 2006 | 220 | 0.060 |
Why?
| | Phenotype | 1 | 2013 | 3158 | 0.050 |
Why?
| | Prognosis | 1 | 2013 | 3982 | 0.050 |
Why?
| | Body Mass Index | 1 | 2013 | 2422 | 0.050 |
Why?
| | Apoptosis | 1 | 2013 | 2555 | 0.050 |
Why?
| | Ultrasonography | 2 | 2022 | 774 | 0.050 |
Why?
| | Follow-Up Studies | 1 | 2013 | 5144 | 0.050 |
Why?
| | Aged | 3 | 2019 | 23995 | 0.050 |
Why?
| | Mice, Inbred C57BL | 1 | 2014 | 5769 | 0.050 |
Why?
| | Urologic Surgical Procedures, Male | 1 | 2023 | 31 | 0.050 |
Why?
| | Mouth Mucosa | 1 | 2023 | 91 | 0.050 |
Why?
| | Time Factors | 1 | 2013 | 6845 | 0.050 |
Why?
| | Constriction, Pathologic | 1 | 2023 | 238 | 0.050 |
Why?
| | Prospective Studies | 1 | 2013 | 7603 | 0.040 |
Why?
| | Animals | 3 | 2022 | 37151 | 0.040 |
Why?
| | Surveys and Questionnaires | 1 | 2013 | 5850 | 0.040 |
Why?
| | Signal Transduction | 1 | 2013 | 5068 | 0.040 |
Why?
| | Autografts | 1 | 2019 | 44 | 0.040 |
Why?
| | Penis | 1 | 2018 | 34 | 0.040 |
Why?
| | Sacrum | 1 | 2019 | 67 | 0.040 |
Why?
| | Urinary Catheters | 1 | 2016 | 10 | 0.030 |
Why?
| | Cystoscopy | 1 | 2016 | 23 | 0.030 |
Why?
| | Pelvic Floor | 1 | 2016 | 22 | 0.030 |
Why?
| | Iatrogenic Disease | 1 | 2016 | 67 | 0.030 |
Why?
| | Child | 2 | 2013 | 21990 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2022 | 3301 | 0.030 |
Why?
| | Adolescent | 1 | 2013 | 21637 | 0.030 |
Why?
| | Mice | 2 | 2022 | 17769 | 0.030 |
Why?
| | Male | 3 | 2018 | 67984 | 0.020 |
Why?
| | Hospitalization | 1 | 2022 | 2195 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2018 | 3014 | 0.020 |
Why?
| | Regression Analysis | 1 | 2011 | 1012 | 0.020 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2006 | 225 | 0.010 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2006 | 174 | 0.010 |
Why?
| | Length of Stay | 1 | 2011 | 1214 | 0.010 |
Why?
| | Amino Acid Substitution | 1 | 2006 | 307 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2016 | 7638 | 0.010 |
Why?
| | Down-Regulation | 1 | 2006 | 635 | 0.010 |
Why?
| | Base Sequence | 1 | 2006 | 2180 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2006 | 2159 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2006 | 2925 | 0.010 |
Why?
| | Models, Molecular | 1 | 2006 | 1598 | 0.010 |
Why?
| | Infant | 1 | 2011 | 9566 | 0.010 |
Why?
| | Child, Preschool | 1 | 2011 | 11142 | 0.010 |
Why?
|
|
Oliver's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|